Corcept (CORT) Q2 Earnings: What To Expect

Corcept Therapeutics (NASDAQ: CORT) is set to report Q2 earnings this Wednesday after market hours, after a mixed recent run. In the prior quarter, the biopharma company missed analysts’ revenue expectations, posting $164.9 million, up 4.9% year over year, while also falling short on EPS versus estimates. For this quarter, the consensus expects revenue to rise 8.4% year over year, down from the 18.7% growth seen in the same period last year. Over the past 30 days, analysts have generally reconfirmed forecasts. Corcept has missed revenue estimates multiple times in the past two years, yet shares were up about 1.9% on average over the last month leading into results.